| HCG Urine
Immunoassay
A safe, cost-effective,
non-invasive, accurate screening for Cancer
Developed in the late 1930's by the renowned oncologist,
the late Dr. Manuel D. Navarro, the test detects the presence of HCG* in
urine. It indicates the presence of cancer cells even before signs or
symptoms develop. Dr. Navarro found HCG to be elevated in all types of
cancers.
The test is based on a theory proposed by Dr. Howard
Beard and other researchers who contend that cancer is related to a
misplaced trophoblast cell that becomes malignant in a manner similar to
pregnancy in that they both secrete HCG. As a consequence, a measure of
the amount of HCG found in the blood or urine is also a measure of the
degree of malignancy. The higher the number, the greater the
severity of the cancer.
Urine, as opposed to blood or serum, is the preferred
specimen for the test. In 1980, Papapetrou and co-authors reported the
correctness of the urine specimen to be used in HCG Immunoassay. In 32
proven cancer cases, the immunoassay test gave 31 positive results using
urine while only 12 positive results were reported using blood. HCG has
been found to undergo glycosylation in the liver as it travels in the
hepatic circulation. Thus, the HCG molecule cannot be detected. The
molecule does not undergo this process in the kidney and therefore the
molecule remains intact in the urine.
The test detects the presence of brain cancer as
early as 29 months before symptoms appear; 27 months for fibrosarcoma of
the abdomen; 24 months for skin cancer; 12 months for cancer of the bones
(metastasis from breast cancer extirpated 2 years earlier).
Currently, many cancer patients take advantage of the
diagnostic accuracy of this test as an indicator of the effectiveness of
their specific mode of therapy. Patients follow a simple direction for
preparing a dry extract from the urine sample. The powdery extract is
mailed to the Navarro Medical Clinic where the HCG testing is performed.
For further information, contact the following
organizations Navarro Medical Clinic Dr. Efren Navarro 3553 Sining Street
Morningside Terrace Santa Mesa, Manila Philippines 011-(632) 714-7442 NavarroMedical@excite.com
Mrs. Erlinda Suarez 631 Peregrine Drive Palatine,
Illinois 60067 (847) 359-3634 [Evening calls appreciated]
PROCEDURE
- Pay for the service.
| **Send a $50 (money order or cashier's
check) to: Erlinda N. Saurez 631 Peregrine Drive Palatine, IL
60067-7005 USA |
- Make a copy of your payment.
- Follow instructions below.
Directions for Urine Sample Preparation
- (1) From an early morning urine, take 50 cc (1.7 oz.)
and add 200 cc (7 oz.) of acetone (can be purchased from hardware
store or pharmacy) and 5 cc (.2 oz) of alcohol, either rubbing or
ethyl. Stir and mix well.
- (2) Let it stand in the refrigerator for 2 hours
until sediment is formed. Throw off about half of the urine-acetone
mixture without losing any sediment. Filter the remainder through a
coffee filter or laboratory filter paper.
- (3) When filtration is over, dry the filter with its
sediment. Fold and wrap in aluminum foil.
- (4)Send by FedEx (First Class mail takes from 5 weeks
to forever; Global Priority Mail takes 10-12 days) to the Navarro
Medical Clinic
Dr. Efren Navarro
3553 Sining Street
Morningside Terrace
Santa Mesa, Manila
Philippines 011-(632)
Include a Xerox copy of the money order or cashier's
check with the patient's name, address, sex, age and a brief clinical
history and/or diagnosis.
| Please allow 4-6 weeks for test result delivery
if they have to be sent by mail to the USA, Canada or Europe.
(HINT: Send it by FedEx and give the lab your e-mail address so
they can send you the results the same day the test is done.) |
This will speed up your receipt of the results by at
least 4-6 weeks.
- (5) WARNING! No
sexual contact for 12 days for female patients before collecting the
urine sample. For males, no sexual contact for 18-24 hours before
collecting the urine sample. DO NOT SEND URINE IF THE PATIENT IS
PREGNANT.
*The HCG Immunity Link By Ruth Sackman
Dr. Howard Beard, a biochemist and cancer patient, found
that he could monitor his cancer by doing the human chorionic
gonadotrophin (HCG) immunoassay to determine how actively his body was
producing unnecessary cells or controlling cell production at a normal
level. This HCG test is used to determine pregnancy, a natural process,
whereby the body is producing excess cells for the development of a fetus.
Dr. Beard's theory was that if HCG levels rose but no fetus was
developing, then abnormal cell production was taking place which, to him,
signified a cancer problem. Dr. Manuel Navarro agreed with this philosophy
and established a measurement to diagnose cancer. A tumor would not be
clinically evident immediately but in time might manifest in men as well
as women.
Two scientists with the West London Hospital, Helen
Davies and S. F. Contractor were interested in one of the most mysterious
biological processes how the body knew when birth was ready at the end of
nine months gestation. They reported in the British journal Nature that
they believe birth is really a process of rejection initiated by the
body's own defense system. The reason this rejection is controlled is
because above normal amounts of HCG appear in the mother's urine during
pregnancy. HCG, they believe, prevents the mother's sentry cells
(lymphocytes) from recognizing the foreign protein (fetus). The HCG levels
remain high until just before birth when a drop in HCG triggers the
rejection of the fetus and birth occurs. Without such recognition,
rejection cannot take effect, ergo, when the HCG titre is above normal on
the HCG test, cancer cell rejection does not take place.
Therefore, Dr. Beard's theory of measuring HCG levels
has a sound scientific basis. Low levels of HCG allow the body to reject
abnormal protein just as it rejects the fetus, and high levels interfere
with the body's ability to build the lymphocytes necessary to effect
rejection of cancer cells.
This theory validates Dr. Beard's conclusion that the
HCG measurement found in the urine was a competent system to diagnose and
monitor cancer cell activity."
Extracted from: CANCER-FREE
NEWSLETTER July 19, 2005 http://www.beating-cancer-gently.com/nl81.html
|
